SPONSORED

In A Potential $100 Billion Psych-e-delics Market(1), Psyched Wellness Ltd. Could Aid Millions with Physical Distress and Sleep Issues

Canada CSE: (PSYC) United States OTC: (PSYCF)

Canaccord Genuity Capital Markets: The Future of Fungi

Press Release June 3, 2021 :

Psyched Wellness Hires Ad Agency, dacs Marketing to Build the Branding and Marketing Strategy for AME-1

Psych-e-delics appear to be going mainstream while displaying growth potential of mind-blowing proportions.

Not only does the US FDA seem to be supportive of research, but also medical studies from the likes of Johns Hopkins Medicine and New York University appear to indicate that such treatments could be helpful.

Although Big Pharma seems to have largely withdrawn from researching and developing psychiatric drugs, further successful trials could potentially reverse this trend.

To date:

P-silo-cyb-in appears to be helpful in treating mental health issues such as depression, anxiety, obsessive-compulsive disorder, PTSD, and possibly even eating disorders.

P-silo-cyb-in can reportedly activate serotonin receptors, or “nature’s own appetite suppressant,” as noted by Psychology Today. “This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight.”(2)

L-S-D may be able to help patients with anxiety disorders and other medical issues, while M-D-M-A-assisted therapy could help treat eating disorders such as anorexia and binge eating.

One company seems to be looking into the potential positive effects of micro-dosing Amanita Muscaria as a way to soothe the body, ease physical distress, and help with sleeping: Psyched Wellness Ltd. Canada CSE: (PSYC) United States OTC: (PSYCF)

Watch Video: Psyched Wellness Ltd.

The Top Reasons to Consider Psyched Wellness Ltd. Canada CSE: (PSYC) United States OTC: (PSYCF)

  1. Psyched Wellness just closed a $6,603,000 Bought Deal private placement.
  2. Canadian company Psyched Wellness appears to be working with the legal fu-ngus Amanita muscaria, which shows potential benefits for mental health treatments.(3)
  3. “Unlike p-silo-cyb-in, it appears to be less hallucinogenic or euphoric but still an entheogenic plant, capable of amplifying emotional experiences and heightened sensory awareness,” as reported by Truffle Report.(4)
  4. Psyched Wellness is led in part by Prof. David Nutt, a psychiatrist at the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept. of Medicine, Hammersmith Hospital, Imperial College London and is the Chair of the Scientific Advisory Board for Compass Pathways.(3)
  5. Prof. David Nutt claims, “As an orally active selective agonist at the newly discovered extra-synaptic GABA-A receptor, Muscimol offers exciting potential opportunities for new medicine development in conditions such as insomnia and sleep disorders, pain and premenstrual syndrome.”(5)
  6. Psyched Wellness claims to see sizable medicinal potential of extracted Amanita Muscaria for medicinal purposes, and as a food supplement.(3)
  7. Psyched Wellness applied with the United States Patent and Trademark Office (USPTO) to register the trademark AME-1, or Amanita Muscaria Extract-1 in connection with the Company’s unique extraction.(6)

Psyched Wellness Ltd. Canada CSE: (PSYC) United States OTC: (PSYCF) May Have Enthralling Potential

After hitting a low of approximately $0.10, the stock rammed forward like a bull to a peak of roughly $0.75 a share in mid-February – good for a return of around 650%. The stock has since pulled back to a current position at approximately $0.33. However, judging from its RSI of about 39.48, it could be nearly oversold. With the potential to see strong moves if its studies indicate promise in soothing the body, easing physical distress, and aiding in sleep- watch out. There’s reason to believe there could be a generationally strong potential for momentum.

If all goes well, it could have similar potential to some of its closest competitors. Just look at some of these stocks’ 52-week low compared to their 52-week peak:

  • Champignon Brands- Low of roughly $0.33, peak of approximately $1.212.
  • Numinus Wellness- Low of nearly $0.19, peak of around $2.45.
  • Mind Medicine Inc.- Low of about $0.19, peak of roughly $5.07.
  • Compass Pathways- Low of approximately $22.51, peak of nearly $61.69.
  • Cybin Inc.- Low of nearly $0.4938, peak of about $2.235.

In addition, Psyched Wellness seems to have plenty of near-term catalysts.

Why Pay Attention to Psyched Wellness Ltd. Canada CSE: (PSYC) United States OTC: (PSYCF)?

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mu-shro-om-derived products and associated consumer packaged goods.

Most importantly, the company appears to be in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.(7)

The Amanita Muscaria mu-shro-om appears to have 3 main components which claim to activate the nervous system: ibotonic acid, muscimol and muscazone. Isolating muscimol compounds appear to treat stress and anxiety, ease muscular pain and promote restorative sleep. Indeed, Muscimol is believed to act as a potent agonist of the Gamma amino-butyric acid A receptor, inhibiting the CNS neurotransmitter and thus promoting sleep.(8)

But Wait, Isn’t Amanita Muscaria Toxic?

Not necessarily.

The toxicity of Amanita Muscaria is believed to have been misunderstood as it has been associated with mu-shro-om poisoning, long believed [incorrectly] to be due to muscarine.3)

However, muscarine is seemingly found in such minute quantities in Amanita Muscaria that it appears to be clinically insignificant. Amanita Muscaria is also believed to not contain any deadly amanitin toxins apparently found in most other poisonous mushro-oms.(3)

In addition, it seems to have a well-documented and long history of traditional use in foods in Europe, Russia, Siberia, North America and Japan.

Companies such Psyched Wellness seem to see sizable medicinal potential of extracted Amanita Muscaria.(3)

Pharmaceutical Industry – The company, and its scientific advisory board, believe that the active compound, muscimol and our unique extraction process have great potential in helping people suffering from depression, anxiety, addictions and more. Led by Prof. David Nutt, the team claims to have commenced R&D to further explore these benefits with the goal of positioning PSYC as a major player in the Pharmaceutical industry.

With regards to food:

Food Supplements Industry – Psyched Wellness plans to finalize its R&D process and claims that it will start sales of its first flagship Amanita Muscaria tincture in the USA as a New Dietary Ingredient (NDI). It also plans to sell it in Canada as a Natural Health Product (NHP). This is believed to be the first psych-e-delic food supplement that may be sold OTC.

This could possibly give the company access to an approximately $34.3 billion global functional mu-shro-om market, according to Mondor Intelligence.(3)

As increasingly health-conscious consumers seek alternatives to modern drugs and medicines, there appears to be a tremendous pathway for Psyched to enhance the health and wellness of millions of consumers with its suite of restorative mu-shro-om products.(9)

The wellness industry is also one that is expected to increase exponentially in the coming years

Worldwide, people seem to have realized the importance of self-care. People want to stay fit, eat well, and reduce stress. The global functional food market could reach approximately $34.3 billion by 2024 and register a CAGR of around 8.04% for the forecasted period (2019-2024).(9)

Specific to medicinal mu-shro-om-s, Food Navigator claims to have found that year-over-year sales for mu-shro-om related products appear to have risen between 200-800%. According to Tachnavio (London, UK), the global medicinal mu-shro-om market may also grow by approximately US$13.88 (2018-22), and progress at a CAGR of more than 9%.(9)

These forecasts appear to be based on the fact that worldwide consumers seem adamant on living happier and healthier lives. As such, the organic and plant-based food industry has evidently soared, with products that claim to offer disease prevention, or increased nutrition and general health. With increased demand for products that seem to promote anti-oxidants and defense from autoimmune conditions, medicinal mu-shro-om-s could be in prime position to answer this market demand.(9)

Because mu-shro-om-s extracts are believed to resist the damaging effects of stress while restoring normal physiological functioning, it is no surprise that Data Bridge Marketing Research suggests that the medicinal mu-shro-om-s market could reach approximately US$78.8 billion by 2025, and grow at a CAGR of about 9.5% during the forecasted 2018-2025 period.(9)

Psyched Wellness Ltd. Canada CSE: (PSYC) United States OTC: (PSYCF) Team Has Years of Experience

This could be one of the most experienced teams in the industry, with a unique expertise on extracting Amanita muscaria for food supplements, and pharmaceuticals.

Jeff Stevens – CEO & Director

Mr. Stevens has 20+ years of capital markets experience and has been an officer and director with several public companies.  He has taken three companies public via reverse takeover, built teams and structured multiple M&A transactions while building successful businesses.

David Shisel — COO

Mr. Shisel is an entrepreneur specializing in the medical green leaf industry in Israel and Europe since 2017. He’s held senior positions with multiple companies in regulated industries with a focus on R&D and product formulation.

Keith Li — CFO

Mr. Li is a CPA, CA with 10+ years experience in financial reporting.  Mr. Li holds Chief Financial Officer positions with several public companies including Quinsam Capital LTD., Harborside Inc. and Pharmadrug Inc.

Michael Nederhoff — Chairman

Currently acts as President of JUUL Labs in Canada overseeing Canadian operations including product launches, organizational structure and P&L responsibility.  Previously served as GM for CytoSport, Inc. overseeing the Canadian launch of Muscle Milk and was one of the first 10 employees at Red Bull Canada where he held senior sales roles for 8+ years.

Terry Booth — Director

Global green leaf industry pioneer and founder of Aurora. An entrepreneur and business leader, Terry has served as President/CEO of 6 other highly successful businesses, including several of Canada’s top 50 fastest-growing companies.

Professor David Nutt  – Advisor

David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Imperial College London. He was previously President of the, European Brain Council, British Association of Psychopharmacology, British Neuroscience Association and European College of Neuropsychopharmacology.

Professor Nutt currently sits as the Chair of the Scientific Advisory Board for COMPASS Pathways and Chair of the Scientific Advisory Board for AWAKN Life Sciences. He is also a member of the Medical Advisory Board of Opiant and sits on the board of Lundbeck Institute Campus.

Janeen Stodulski – Director

Janeen brings more than 30 years in diverse tax, financial, and business consulting experience to the table. She has gained extensive accounting experience through her senior roles in public practice, as a partner at MNP and Client Service Manager at Grant Thornton LLP as well as several board positions and C-suite roles in a variety of companies. Janeen extensive expertise allows her to provide outside the box strategies and solutions in addition to comprehensive accounting services.

Nick Kadysh – Director

Head of Corporate Affairs at JUUL Labs Canada. Formerly served as Government Affairs & Public Leader at GE Healthcare and Director of Public Affairs for Red Bull Canada.

Following a career as a political advisor, Nick specializes in managing regulatory risk for companies in the food and drug industry.

Dr. Dawn DeCunha — Advisor

Dr. Dawn DeCunha is a clinical psychologist, with an active practice in Toronto, Canada. She is a graduate of the prestigious postgraduate program in psych-e-delic Research and Therapy, at the California Institute of Integral Studies. Her training in psych-e-delic research and therapy is recognized by Health Canada, the FDA as well as the European Medicines Agency as highly specialized training in novel pharmaceutical treatment protocols for Phase 11b clinical trials with scheduled drugs. Dr. DeCunha is currently the Lead Therapist for Phase 2 clinical trials investigating Treatment Resistant Depression and P-silo-cyb-in at CAMH in Toronto.

Dr. Andrew Kohler — Advisor

Dr. Kohler is the founder and owner of Callingwood Crossing Medical Center, which he has built over the years through a series of acquisitions. He is actively involved raising money for Edmonton based health and education initiatives and also works part time teaching medical students as a Clinical Professor of Medicine from the University of Alberta School of Medicine and Dentistry.  Mr. Kohler participated in various pharmaceutical trials and studies. Mr. Kohler is an associate clinical professor of medicine at the University of Alberta.

Brian Tancowny — Advisor

Mr. Brian Tancowny has over 25 years of experience in Research and Development with government, academic, and private sector partners. He has built and managed diverse research portfolios in animal and human health supplements, personal care products, and medical therapeutics. He has led diverse research teams in creating new and innovative research projects that have bridged private and government collaborators with a particular focus on end-stage development and product marketing. Mr. Tancowny is presently a quality- assurance manager with an in-depth understanding of the challenges of operational issues in start-up companies to regulatory procedures and policies.

Kevin Feeney – Advisor

Kevin Feeney, PhD, JD, is a cultural anthropologist and lawyer currently working as a Program Director and Instructor in Interdisciplinary Studies – Social Sciences at Central Washington University. His primary research interests include examining legal and regulatory issues surrounding the religious and cultural use of p-sycho-act-ive substances, with an emphasis on p-eyo-te and a-yah-uas-ca, and exploring modern and traditional uses of Amanita muscaria, with a specific focus on medicinal use and preparation practices.

Aaron Slater — Advisor

Aaron Slater has over twenty-five years of experience in Corporate Finance, M&A and Merchant Banking. He has been involved in over US$8 billion in transactions including a number of buy-out deals in Latin America, USA and Canada following from which he continues to maintain his involvement through being a director or shareholder. Currently, Aaron is a shareholder and executive director of one of the largest organic farms in Latina America. Aaron has worked with various High Net Worth Individuals, Family Offices and Hedge Funds to provide them a private equity capability that includes deal sourcing, structuring, investment oversight and managing liquidity events. These efforts have resulted in numerous successful investments with a specific focus on agriculture, natural resources and sustainability.

The Top Reasons to Consider Psyched Wellness Ltd. Canada CSE: (PSYC) United States OTC: (PSYCF)

  1. Psyched Wellness just closed a $6,603,000 Bought Deal private placement.
  2. Canadian company Psyched Wellness appears to be working with the legal fu-ngus Amanita muscaria, which shows potential benefits for mental health treatments.(3)
  3. “Unlike p-silo-cyb-in, it appears to be less hallucinogenic or euphoric but still an entheogenic plant, capable of amplifying emotional experiences and heightened sensory awareness,” as reported by Truffle Report.(4)
  4. Psyched Wellness is led in part by Prof. David Nutt, a psychiatrist at the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept. of Medicine, Hammersmith Hospital, Imperial College London and is the Chair of the Scientific Advisory Board for Compass Pathways.(3)
  5. Prof. David Nutt claims, “As an orally active selective agonist at the newly discovered extra-synaptic GABA-A receptor, Muscimol offers exciting potentialy opportunities for new medicine development in conditions such as insomnia and sleep disorders, pain and premenstrual syndrome.”(5)
  6. Psyched Wellness claims to see sizable medicinal potential of extracted Amanita Muscaria for medicinal purposes, and as a food supplement.(3)
  7. Psyched Wellness applied with the United States Patent and Trademark Office (USPTO) to register the trademark AME-1, or Amanita Muscaria Extract-1 in connection with the Company’s unique extraction.(6)
Source 1: https://www.businessinsider.com/eight-capital-analyst-mindmed-psychedelics-industry-ammar-shah-2020-5
Source 2: https://www.psychologytoday.com/us/blog/the-antidepressant-diet/201008/serotonin-what-it-is-and-why-its-important-weight-loss
Source 3: https://psyched-wellness.com/wp-content/uploads/2020/12/Psyched-Wellness-December-2020.pdf
Source 4: https://www.truffle.report/psyched-wellness-legal-amanita-muscaria-mushroom-study/
Source 5: https://www.bloomberg.com/press-releases/2021-01-14/psyched-wellness-completes-initial-data-review-to-determine-clinical-path-for-muscimol
Source 6: https://psyched-wellness.com/psyched-wellness-submits-an-application-to-register-a-trademark-for-the-companys-unique-extraction/
Source 7: https://www.bloomberg.com/press-releases/2020-12-15/psyched-wellness-successfully-completes-extraction-of-a-legal-psychedelic-mushroom
Source 8: https://psyched-wellness.com/amanita-muscara/